Therefore, HDAC inhibitors, via their epigenetic reprogramming capacity, can alter the expression of immunomodulatory factors, including PD-L1, thus rendering their application a promising strategy to amplify the anti-tumor potential of PD-1/PD-L1 inhibitors, in the context of combination therapeutic regimens for TETs. Here, HDAC9 is linked to neoplasm.